litlas
ログインアカウント作成

Hans Lennernäs

1992–2025 年に発表

109
論文数
18,858
被引用数
70
h 指数
104
i10 指数

被引用数

Hans Lennernäs の年別被引用数1967 年: 被引用 1 件1975 年: 被引用 1 件1993 年: 被引用 2 件1994 年: 被引用 3 件1995 年: 被引用 17 件1996 年: 被引用 36 件1997 年: 被引用 48 件1998 年: 被引用 67 件1999 年: 被引用 67 件2000 年: 被引用 72 件2001 年: 被引用 112 件2002 年: 被引用 89 件2003 年: 被引用 117 件2004 年: 被引用 124 件2005 年: 被引用 144 件2006 年: 被引用 161 件2007 年: 被引用 239 件2008 年: 被引用 171 件2009 年: 被引用 193 件2010 年: 被引用 217 件2011 年: 被引用 166 件2012 年: 被引用 209 件2013 年: 被引用 245 件2014 年: 被引用 209 件2015 年: 被引用 132 件2016 年: 被引用 158 件2017 年: 被引用 112 件2018 年: 被引用 108 件2019 年: 被引用 408 件2020 年: 被引用 517 件2021 年: 被引用 446 件2022 年: 被引用 287 件2023 年: 被引用 240 件2024 年: 被引用 387 件2025 年: 被引用 188 件2026 年: 被引用 6 件1968〜1974 年は被引用が無いため表示していません1976〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,157 件、この内訳の 19%イギリス: 引用元論文 507 件、この内訳の 8.3%ドイツ: 引用元論文 391 件、この内訳の 6.4%中国: 引用元論文 356 件、この内訳の 5.8%スウェーデン: 引用元論文 316 件、この内訳の 5.2%インド: 引用元論文 276 件、この内訳の 4.5%スイス: 引用元論文 197 件、この内訳の 3.2%イタリア: 引用元論文 183 件、この内訳の 3%日本: 引用元論文 182 件、この内訳の 3%ベルギー: 引用元論文 164 件、この内訳の 2.7%フランス: 引用元論文 144 件、この内訳の 2.4%オランダ: 引用元論文 134 件、この内訳の 2.2%
0%19%その他 34.3%

機関

分野

  • Pharmacology, Toxicology and Pharmaceutics33.3%
  • Medicine32.7%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Computer Science6.4%
  • Materials Science4.1%
  • Chemistry4.1%
  • その他8.1%

トピック

  • Drug Solubulity and Delivery Systems11.5%
  • Advanced Drug Delivery Systems6.4%
  • Drug Transport and Resistance Mechanisms5.6%
  • Computational Drug Discovery Methods4.3%
  • Analytical Chemistry and Chromatography3.8%
  • Crystallization and Solubility Studies3.4%
  • その他65%

共著者

全論文

検索で開く
  1. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

    著者: Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah, John R. Crison - Pharmaceutical Research 1995 被引用: 5,323

  2. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches

    著者: David Dahlgren, Hans Lennernäs - Pharmaceutics 2019 被引用: 248

  3. Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocation

    著者: David Dahlgren, Hans Lennernäs - Biomedicine & Pharmacotherapy 2023 被引用: 74

  4. Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies

    著者: David Dahlgren, Markus Sjöblom, Per M. Hellström, Hans Lennernäs - Frontiers in Pharmacology 2021 被引用: 134

  5. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma

    著者: Jaafar Khaled, Maria Kopsida, Hans Lennernäs, Femke Heindryckx - Cells 2022 被引用: 75

  6. The Critical Role of Passive Permeability in Designing Successful Drugs

    著者: Li Di, Per Artursson, Alex Avdeef, Leslie Z. Benet, J. Brian Houston, Manfred Kansy, Edward H. Kerns, Hans Lennernäs, Dennis A. Smith, Kiyohiko Sugano - ChemMedChem 2020 被引用: 109

  7. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs

    著者: Duxin Sun, Hans Lennernäs, Lynda S. Welage, Jeffery L. Barnett, Christopher P. Landowski, David R. Foster, David Fleisher, Kyung‐Dall Lee, Gordon L. Amidon - Pharmaceutical Research 2002 被引用: 441

  8. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification

    著者: Nehal A. Kasim, Marc Whitehouse, Chandrasekharan Ramachandran, Marival Bermejo, Hans Lennernäs, Ajaz Hussain, Hans E. Junginger, Salomon Stavchansky, Kamal K. Midha, Vinod P. Shah, Gordon L. Amidon - Molecular Pharmaceutics 2003 被引用: 844

  9. Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells

    著者: Maria Kopsida, Ada Lerma Clavero, Jaafar Khaled, David Balgoma, Clara Luna-Marco, Azazul Chowdhury, Sofi Sennefelt Nyman, Fredrik Rorsman, Charlotte Barbier, Peter Bergsten, Hans Lennernäs, Mikael Hedeland, Femke Heindryckx - Molecular Metabolism 2023 被引用: 26

  10. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review

    著者: Joseph P. O’Shea, Patrick Augustijns, Martin Brandl, David J. Brayden, Joachim Brouwers, Brendan T. Griffin, René Holm, Ann-Christin Jacobsen, Hans Lennernäs, Zahari Vinarov, Caitríona M. O’Driscoll - European Journal of Pharmaceutical Sciences 2021 被引用: 67

  11. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model

    著者: Xianhua Cao, Seth Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho‐Chul Shin, Hans Lennernäs, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, Duxin Sun - Pharmaceutical Research 2006 被引用: 385

  12. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited

    著者: Ahmad Al‐Saffar, Hans Lennernäs, Per M. Hellström - Neurogastroenterology & Motility 2019 被引用: 93

  13. Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach

    著者: Susanne Winiwarter, Nicholas M. Bonham, Fredrik Ax, Anders Hallberg, Hans Lennernäs, Anders Karlén - Journal of Medicinal Chemistry 1998 被引用: 452

  14. Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation

    著者: Gudmundur Johannsson, A. G. Nilsson, Ragnhildur Bergthorsdottir, Pia Burman, Per Dahlqvist, Bertil Ekman, Britt Edén Engström, Tommy Olsson, Óskar Ragnarsson, Mats Ryberg, Jeanette Wahlberg, Beverly M. K. Biller, John P. Monson, Paul M. Stewart, Hans Lennernäs, Stanko Skrtic - The Journal of Clinical Endocrinology & Metabolism 2011 被引用: 328

  15. Intestinal permeability and its relevance for absorption and elimination

    著者: Hans Lennernäs - Xenobiotica 2007 被引用: 295

  16. Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods

    著者: David Dahlgren, Carl Roos, Erik Sjögren, Hans Lennernäs - Journal of Pharmaceutical Sciences 2014 被引用: 123

  17. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

    著者: Charlotte Ebeling Barbier, Femke Heindryckx, Hans Lennernäs - International Journal of Molecular Sciences 2021 被引用: 50

  18. Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma

    著者: Carlemi Calitz, Jenny Rosenquist, Oliver Degerstedt, Jaafar Khaled, Maria Kopsida, Mårten Fryknäs, Hans Lennernäs, Ayan Samanta, Femke Heindryckx - Scientific Reports 2023 被引用: 41

  19. ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO

    著者: Niclas Petri, Christer Tannergren, Birgit Holst, Fred A. Mellon, Yongping Bao, Geoff W. Plumb, Jim Bacon, Karen O’Leary, Paul A. Kroon, Lars Knutson, Patrik Forsell, Thomas Eriksson, Hans Lennernäs, Gary Williamson - Drug Metabolism and Disposition 2003 被引用: 221

  20. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma

    著者: Fredrik Kullenberg, Oliver Degerstedt, Carlemi Calitz, Nataša Pavlović, David Balgoma, Johan Gråsjö, Erik Sjögren, Mikael Hedeland, Femke Heindryckx, Hans Lennernäs - Cells 2021 被引用: 70

  21. In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects

    著者: Erik Sjögren, Bertil Abrahamsson, Patrick Augustijns, D. E. Becker, Michael B. Bolger, Marcus E. Brewster, Joachim Brouwers, Talia Flanagan, Matthew D. Harwood, Christian Heinen, René Holm, Hans‐Paul Juretschke, Marlies Kubbinga, Anders Lindahl, Viera Lukáčová, Uwe Münster, Sibylle Neuhoff, Mai Anh Nguyen, Achiel Van Peer, Christos Reppas, Amin Rostami‐Hodjegan, Christer Tannergren, Werner Weitschies, Clive Wilson, Patricia Zane, Hans Lennernäs, Peter Langguth - European Journal of Pharmaceutical Sciences 2014 被引用: 274

  22. The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids

    著者: Eva Persson, Ann-Sofie Gustafsson, Anders S. Carlsson, Ralf Nilsson, Lars Knutson, Patrick Forsell, Gunilla Hanisch, Hans Lennernäs, Bertil Abrahamsson - Pharmaceutical Research 2005 被引用: 264

  23. Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets

    著者: Dag Nyholm, Håkan Askmark, Cecilia Gomes–Trolin, Tina W. Knutson, Hans Lennernäs, Christer Nyström, Sten‐Magnus Aquilonius - Clinical Neuropharmacology 2003 被引用: 237

  24. Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women

    著者: Anders Lindahl, Anna‐Lena Ungell, Lars Knutson, Hans Lennernäs - Pharmaceutical Research 1997 被引用: 408